Clinical Relevance of Tumor Markers in Epithelial
Ovarian Cancer
Holubec L., jr.1, Fínek J.1, Topolčan O.2, Bouda J.3, Rokyta Z.3
1Onkologické a radioterapeutické oddělení FN, Plzeň, přednosta prim. MUDr. J. Fínek, Ph.D. 2ONM – úsek imunodiagnostiky FN, Plzeň, vedoucí prof. MUDr. O. Topolčan, Ph.D. 3Gynekologicko-porodnická klinika FN, Plzeň, přednosta doc. MUDr. Z. Rokyta, CSc. |
|
Summary:
Aim of Study: The authors present the view of possible usage of tumour markers in epithelial
ovarian cancer, and they aim at their use in routine clinic practice.
Type of Study: Review article.
Setting: Oncology and Radio-Therapeutic Department, Faculty Hospital, Pilsen.
Subject and Methods of the Study: Summary of data published in Czech and foreign professional
literature.
Conclusion: In case of epithelium tumours of ovaries, CA 125 is the tumour marker of the fi rst choice.
For the reason of low sensitivity, it is not possible to use the tumor markers for screening and
primary diagnostics. Regarding prognoses, high pre-operational levels of CA 125 are considered
unfavourable. At the same time the study demonstrates that CA 125 levels monitoring in the course
of chemotherapy appears to be one of the most signifi cant indicators of chemotherapy effects and,
therefore, also of prognoses. Regular CA 125 monitoring in the course of follow up can contribute
to early detection of tumour disease relapses. The optimal time interval for monitoring seems to be
three months for the period of the fi rst two years, and then six-month interval. Other tumour markers
used in routine clinic practice are mainly CA 19-9 and CA 72-4, particularly in case of mucinoid
epithelium tumours. However, these markers are of subsidiary importance only.
Key words:
epithelial ovarian cancer, tumor markers, CA 125
|